Safety and efficacy of the combination of once-daily tadalafil and alpha-1 blocker in Japanese men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A randomized, placebo-controlled, cross-over study Objectives: To evaluate the safety and efficacy of tadalafil plus a 1 -blocker combination therapy in Japanese patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
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Introduction
BPH, a common disease in elderly men, is often associated with LUTS. This condition, known as "LUTS/BPH" significantly affects the QOL and labor productivity of patients. 1 Uroselective a 1 -blockers (a 1 -blockers) and 5-ARIs are the standard treatment for patients with LUTS/BPH. Although a 1 -blockers are commonly used for initial treatment, combination therapy with an a 1 -blocker and a 5-ARI is also recommended for treating patients with substantial prostatic enlargement.
A recent survey showed that approximately 50% of Japanese patients with LUTS/BPH are dissatisfied with their current drug therapy, and >50% of patients request changes in their prescriptions for LUTS/BPH. 6 For such patients, a new BPH therapeutic agent that inhibits PDE5, tadalafil, provides additional treatment options. Furthermore, combination with an a 1 -blocker might exert a superior therapeutic effect compared with monotherapies. Both agents are potential vasodilators, and care must be taken as their combination can cause a decrease in BP. 7 Although the effectiveness and safety of tadalafil combined with various a 1 -blockers has not yet been established, several studies have reported the effectiveness and safety of this combination therapy. Safety assessments from several clinical studies, including a large randomized placebo-controlled study, showed that although tadalafil combined with tamsulosin or other a 1 -blockers does not decrease BP, combining tadalafil with a non-uroselective a 1 -blocker, such as doxazosin, enhances the hypotensive effect of tadalfil. [7] [8] [9] The possible hypotensive-enhancing effect of the combination of tadalafil with an a 1 -blocker, however, is still a clinical concern for physicians and needs to be better clarified. Furthermore, although several studies have suggested that combination therapy of a PDE5 inhibitor with an a 1 -blocker has an additive effect, the results are inconclusive, largely because few randomized, double-blinded, placebo-controlled studies with a large sample size have been carried out. [10] [11] [12] In the present study, a comparatively larger sample size, as well as a double-blind, randomized, placebo-controlled, crossover study design, was used to evaluate the safety and efficacy of combination therapy with tadalafil and an uroselective a 1 -blocker.
Methods
The present multicenter, randomized, double-blind, placebocontrolled, two-treatment, two-period cross-over study was carried out at 17 institutions in Japan and included Japanese patients with LUTS/BPH currently undergoing a 1 -blocker treatment (ClinicalTrials.gov: NCT02431754, JAPIC: Japic CTI-152895). All patients were required to maintain a base a 1 -blocker therapy (tamsulosin 0.2 mg once daily or silodosin 4 mg twice daily) without any change of dose throughout the study. After a 4-week screening period, eligible patients were randomized to one of two arms in a two-period cross-over design (Fig. 1 ). Patients were administered tadalafil 5 mg once daily or a placebo for 8 weeks. IWRS was utilized for randomization, which was stratified by current a 1 -blocker therapy.
The study protocol was approved by the IRB of each participating medical institution, and carried out in accordance with the Declaration of Helsinki and GCP. All patients provided written informed consent.
Major inclusion criteria were Japanese men aged at least 45 years with continuous LUTS/BPH for the previous 6 months or longer, who consistently received a 1 -blocker treatment at a constant dose (tamsulosin 0.2 mg once daily or silodosin 4 mg twice daily) as a base therapy for the previous 8 weeks or longer. Other inclusion criteria were patients with a 20 mL or greater prostate volume and a total IPSS of at least 12. Patients with hypotension-related symptoms (e.g. dizziness, light-headedness, loss of consciousness and syncope) were excluded from the study, as well as those who were using medications other than a 1 -blockers for treatment of BPH, or had been treated for OAB within 4 weeks before baseline. Patients were also excluded if they were being treated for OAB or ED, or had been treated for ED, or expressed an interest in receiving ED or OAB treatment during the study period.
Safety was assessed by TEAEs, vital signs (BP and pulse) and an orthostatic test. The orthostatic test was carried out at the start and end of each treatment period to determine BP and pulse fluctuations during postural changes from the supine to standing position. Orthostatic hypotension was determined by clinical investigators based on the following criteria: a decrease of at least 20 mmHg in SBP, a decrease in SBP to <90 mmHg, a decrease of at least 10 mmHg in DBP within 3 min after standing up from the supine position, or an increase in pulse rate from at least 30 b.p.m. to >120 b.p.m. within 5 min after standing up. 13, 14 The primary efficacy end-point, responses to TPQ, was a patient-reported outcome assessed after the second treatment period. Patients evaluated which therapy was more preferable for BPH treatment that was used in the first or second treatment periods. Secondary efficacy end-points were changes from baseline in IPSS scores (total, storage-symptom, voiding-symptom and IPSS-QOL scores), PGI-I 15 The a 1 -blocker given was tamulosin 0.2 mg once daily or silodosin 4 mg twice daily.
BPH (i.e. voiding difficulty, nocturia, feeling of incomplete bladder emptying, increased daytime frequency, urgency, weak stream, straining and post-micturition dribble).
Clinically meaningful improvement was defined as a ≥25% decrease in total IPSS score, or at least a 3-point drop from baseline. [16] [17] [18] [19] [20] Second treatment: discontinued n = 1 (1.2%) 
Statistical analysis
The sample size of the study was calculated based on the TPQ results. Assuming that the combination therapy was preferred by 50% and 65% of the patients under the null and alternative hypotheses, respectively, a sample size of 113 patients had a 90% power to detect a statistically significant difference using a one-sample v 2 -test at a two-sided 5% significance level. With a predicted dropout rate of 20%, we determined that 142 patients (71 per treatment group) would be required.
Efficacy and safety analyses were carried out for the patients who were randomized and received at least one dose of the study drug. In the analysis of TPQ, patients without TPQ results were excluded from the analysis. Baseline was defined as the last non-missing value before starting the administration of the agents in each period. For the continuous efficacy and safety parameters, a mixed effects model based on repeated measurements was used. The McNemar test was used for categorical variables, such as the incidence of TEAEs. TEAEs associated with hypotension were defined as TEAEs coded as "hypotension" or "orthostatic hypotension" using MedDRA/J, version 18.1 (http://www.meddra.org).
The data from the tadalafil 5 mg/placebo and placebo/tadalafil 5 mg groups were integrated and reclassified as combination therapy (a 1 -blocker and tadalafil) and monotherapy (a 1 -blocker and placebo) groups for the analyses.
Results
The disposition of patients and reasons for study discontinuation are shown in Figure 2 . From the 187 patients initially screened, 171 were randomized to the tadalafil 5 mg/placebo (n = 85) and placebo/tadalafil 5 mg (n = 86) groups. Among these, 74 patients (87.1%) in the tadalafil 5 mg/placebo group and 78 patients (90.7%) in the placebo/tadalafil 5 mg group completed the second treatment period. The mean age of the patients was 61.7 AE 6.0 years; 58.5% were aged <65 years. The a 1 -blockers, tamsulosin 0.2 mg and silodosin 4 mg, were concomitantly administered in 80.1% and 19.9% of the patients, respectively (Table 1) .
In the orthostatic test, there were no statistically significant differences in the mean change from baseline to week 8 in SBP or DBP between the combination therapy and monotherapy groups. The mean change at week 8 from baseline in the SBP and DBP orthostatic test results in the combination therapy group were 0.6 AE 10.4 and 0.7 AE 6.7 mmHg, respectively. No patients were considered orthostatic hypotensive on testing. The mean change at week 8 from baseline in the pulse rate orthostatic test results was 0.9 AE 6.4 b.p.m. in the combination therapy group and À0.7 AE 6.9 b.p.m. in the monotherapy group. The mean change in orthostatic pulse rate was statistically significant (P = 0.0115) between the treatment groups ( Table 2) . In vital signs, the mean change from baseline to week 8 in SBP was À0.1 mmHg and 0.5 mmHg in the combination therapy group and monotherapy group, respectively. The treatment difference in SBP (LS mean: À0.9 mmHg) was not statistically significant between the treatment groups. For DBP, the mean change from baseline to week 8 was À2.2 mmHg and À0.6 mmHg in the combination therapy group and monotherapy group, respectively. The reduction in the combination therapy group was statistically significant (P = 0.0194) compared with the monotherapy group. For pulse, the mean change from baseline to week 8 was 1.1 b.p.m. and À0.3 b.p.m. in the combination therapy group and monotherapy group, respectively. A statistically significant change was observed (P = 0.0313; Table 3 ).
The incidence of TEAEs in the combination therapy and monotherapy groups was 28.1% and 24.2% (47/167 and 39/ 161), respectively (P = 0.8927). Most of the events were mild in severity. Major TEAEs in the combination therapy group were nasopharyngitis (7.8%, 13/167) and abdominal discomfort (2.4%, 4/167). AEs led to study discontinuation for eight patients (4.8%) in the combination therapy group and three patients (1.9%) in the monotherapy group (Table 4) . No serious AEs were observed.
No TEAEs associated with hypotension as defined in the statistical analysis section were observed. However, TEAEs possibly associated with hypotension were observed in one patient. That patient had three TEAEs (dizziness, dizziness postural, nausea) during treatment with tadalafil and tamsulosin, and discontinued the study. These TEAEs were considered by the investigator to be possibly related to the study drug.
Patient responses to TPQ, the primary efficacy end-point, showed that 56.7% (89/157) patients preferred the combination therapy to monotherapy; however, the difference was not statistically significant (95% CI 48.94-64.44, P = 0.0937).
The LS mean change in IPSS total score showed a larger numerical decrease in the combination therapy group (À2.5) compared with the monotherapy group (À1.8) after 8 weeks of treatment (difference: À0.7, 95% CI À1.69-0.26, P = 0.1485; Fig. 3 ), but the difference was not statistically significant. The percentage of patients whose total IPSS score decreased by ≥25% from baseline was significantly larger (P = 0.0290) in the combination therapy group (35.7%, 56/ 157) than in the monotherapy group (24.4%, 38/156; Table 5 ). The LS mean change in IPSS voiding subscore was À2.0 and À1.3 in the combination therapy and monotherapy groups, respectively, indicating a statistically significant greater improvement in the combination therapy group (difference: À0.7, 95% CI À1.36, À0.02, P = 0.0442). No significant differences were observed in the IPSS storage or QOL scores (Fig. 3) . PGI-I scores showed that a larger percentage of patients in the combination therapy group (61.1%, 102/167) reported improvement in LUTS/BPH symptoms than in the monotherapy group (53.4%, 86/161); however, the difference was not statistically significant (P = 0.0943). Furthermore, DRAQ results showed that significantly higher percentages of patients in the combination therapy group reported improvement in feelings of incomplete emptying (48.5%, 81/167, P = 0.0033) and weak stream (42.5%, 71/167, P = 0.0350) than in the monotherapy group (34.8%, 56/161 and 32.9%, 53/161, respectively, Table 5 ).
Discussion
The clinical benefit and potential risk of tadalafil in combination with an a 1 -blocker have yet to be fully determined. Therefore, in the present study, we evaluated the safety and efficacy of combination therapy with tadalafil and one of two a 1 -blockers (tamsulosin or silodosin) in Japanese patients with LUTS/BPH.
No TEAEs associated with hypotension or orthostatic hypotensive symptoms (as evaluated by the orthostatic test) were observed. Although one patient treated with tadalafil and tamsulosin experienced three TEAEs (dizziness, dizziness postural, nausea), it was not clear that these TEAEs were associated with a reduction in BP. The incidence of these TEAEs was similar to the incidence of dizziness in tadalafil alone that we reported for previous studies. 21 In vital signs, the treatment difference of DBP and pulse were statistically significant between the combination therapy and the monotherapy groups. However, there were no individual patients considered to have a clinically meaningful decrease in BP or increase in pulse. Therefore, these results suggest that tadalafil plus a 1 -blocker combination therapy can be administered safely without substantial BP-decreasing effects.
Kloner et al. investigated the BP-lowering effect of tadalafil in combination with doxazosin or tamsulosin in healthy volunteers, and reported that the combination of tamsulosin and tadalafil did not decrease BP. 7 This is further supported by the present study that showed that combination therapy with tadalafil and a uroselective a 1 -blocker resulted in no TEAEs associated with hypotension or negative orthostatic test outcomes.
In addition, the incidences of TEAEs were not significantly different between the combination therapy and monotherapy treatment groups. Among the TEAEs related to the study drug, the incidence rate of gastrointestinal disorders was higher in the combination therapy group than in the monotherapy group. Furthermore, more patients in the combination therapy group discontinued the study because of TEAEs related to the study drug than those in the monotherapy group. However, all of the TEAEs were previously known to be associated with tadalafil or a 1 -blockers, and the majority of the events were determined to be mild.
Although the results of the TPQ were not statistically significant, patient preference for the combination therapy was numerically greater than that for the monotherapy. Another index based on questions similar to those used in the TPQ survey, the GAQ, was used by Bechara et al. to assess patient satisfaction with treatment. 10 Although the sample size was small and the study included patients with LUTS/BPH complicated by ED, their results showed that the level of patient satisfaction with the combination therapy was markedly higher than it was with the monotherapy. The questions (TPQ) in the present study focused on BPH symptoms, and did not incorporate evaluation of changes in ED symptoms. We excluded patients with ED or those who had received ED treatment, which we considered might have caused the difference in patient satisfaction with the treatments.
Approximately two-thirds of patients report relief from LUTS with a 1 -blocker therapy. 3 However, Tsujii et al. reported that according to efficacy assessment standards for the treatment of BPH, excellent or good improvement was achieved with a 1 -blocker therapy in 20-40% of patients. 22 These results show that although treatment with a 1 -blockers does provide significant relief from LUTS, a noteworthy number of patients still have residual LUTS despite treatment. Thus, tadalafil in combination with an a 1 -blocker appears to be useful for patients with residual LUTS, including those who previously used a 1 -blockers alone.
The percentage of patients whose total IPSS score improved by ≥25% from baseline was significantly larger in the combination therapy group than in the monotherapy group. Furthermore, changes in the IPSS voiding symptom score from baseline were statistically significantly larger in the combination therapy group than in the monotherapy group. These results suggest that treatment with tadalafil plus a 1 -blockers exerts a combinational effect in improving LUTS, especially voiding symptoms. Furthermore, as tadalafil and a 1 -blockers work on the lower urinary tract by different mechanisms of action, their combination might have been more effective. In contrast, no differences in the IPSS storage symptom or IPSS-QOL scores were observed between the combination and monotherapy groups.
In the present study, we included patients who presented with LUTS/BPH for 6 months and had been treated with a 1 -blocker for at least 8 weeks. Patients requiring treatment for OAB were excluded. Therefore, the IPSS total and storage symptom scores at baseline in the present study were lower than what we have reported for previous studies. 23, 24 This might be the reason why the study included patients with stable storage symptoms. Furthermore, the treatment period of tadalafil was shorter than what we have reported for previous studies. These could explain the reason why significant improvement with combination therapy was not observed in the IPSS total and storage symptom score.
In summary, the present study confirmed that combination therapy with tadalafil 5 mg and an uroselective a 1 -blocker, tamsulosin or silodosin, did not result in a clinically meaningful decrease in BP and was tolerable in Japanese patients with LUTS/BPH. Responses to the Treatment Preference Questionnaire, the primary efficacy end-point, showed that patients tended to prefer combination therapy to monotherapy, though this was not statistically significant. Other efficacy results showed that the combination therapy was more effective against voiding symptoms compared with a 1 -blocker monotherapy. Based on these results, patients who do not adequately respond to a 1 -blockers alone might benefit from a tadalafil 5 mg plus a 1 -blocker combination therapy. However, the risks and benefits of this therapy should be amply considered in patients with LUTS/BPH. 
